Repligen raises $1B in convertible notes to refinance debt and fund M&A
What's the deal? RepligenDealroom has a profile for this one. Try Dealroom →, the Massachusetts-based bioprocessing company, is issuing $1 billion of 0.25% convertible senior notes due 2031. About $541.4 million of the new notes will swap for $456.8 million of its existing 1.00% notes due 2028, while $458.6 million will be sold for cash. The transaction is expected to close around November 6, 2026.
Why now? The deal "proactively addresses the upcoming maturity of our 2028 Notes," said chief financial officer Jason Garland. It lowers Repligen's coupon from 1.00% to 0.25%, extends its debt by three years, and leaves roughly $143.2 million of the 2028 notes outstanding.
What's the endgame? Repligen closed its roughly $1.5 billion acquisition of BioLife SolutionsDealroom has a profile for this one. Try Dealroom → on October 6, expanding into cell therapy. The new cash — after a $120 million share repurchase to facilitate the deal — goes to working capital, general corporate purposes, and possible further acquisitions.
The conversion price is set at about $226.37 per share, a 20% premium over the October 29 closing price.
By the numbers: The timing follows a strong quarter. Third-quarter revenue rose 12.5% organically, and Repligen lifted its 2026 revenue outlook to $844–852 million, a figure that now includes BioLife.
The signal: At $1 billion, this ranks among the largest US post-IPO convertible deals on record, in the 93rd percentile of 781 such rounds. By trading higher-coupon debt for cheaper, longer-dated paper while raising fresh cash, Repligen is building capacity for the "disciplined M&A" Garland flagged — a sign of how acquisitive bioprocessing players are using convertibles to fund consolidation.
Read more: pr.lakeoconeebreeze.net
Image credit: Generated with Gemini
